Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease

Clinical Cardiology

Volumn 13, Issue 3, 1990, Pages 165-170

  Rowe, G G ^a   Folts, J D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

aspirin; coronary thrombosis; dipyridamole; myocardial infarction; platelet aggregation; transient ischemia

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE;

ADULT; AGED; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; REVIEW;

ANIMAL; ASPIRIN; CORONARY DISEASE; CORONARY THROMBOSIS; DIPYRIDAMOLE; DOGS; DRUG THERAPY, COMBINATION; HUMAN;

EID: 0025271075     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.4960130304     Document Type: Review

References (80)

1. Platelet aggregation in partially obstructed vessels and their elimination with aspirin
2. Blood flow reductions in stenosed canine coronary arteries: Vasospasm of platelet aggregation
3. In vitro studies of the platelet aggregation‐release reaction
4. Clinical application of the platelet aggregation‐release reaction to vascular disease
5. Experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance
6. Possible platelet thrombi formation in dogs and human femoral arteries
7. Cerebral embolism
8. Observations of the fundus oculi in transient monocular blindness
9. Platelet thrombus formation in stenosed monkey carotid arteries, inhibited by aspirin, restored by epinephrine
10. Coronary artery thrombosis in patients with unstable angina
11. Angiographic morphology and the pathogenesis of unstable angina pectoris
12. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
13. Inlracoronary thrombolysis in evolving myocardial infarction
14. Elective intraeoronary thrombolysis in acute myocardial infarction and unstable angina pectoris
15. Demonstration of thrombus and complex atheroma by in vivo angioscopy in patients with unstable angina pectoris
16. A perspective of coronary disease seen through the arteries of living man
17. The relation of coronary thrombosis to ischaemic myocardial necrosis
18. Plaque rupture with severe preexisting stenosis precipitating coronary thrombosis: Characteristics of coronary athcroslccrotic plaques underlying fatal occlusive thrombi
19. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death
20. Mural platelet microthrombi and major acute lesions of main epicardial arteries in sudden coronary death
21. Platelet aggregates in the intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease
22. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
23. Impaired platelet/connective‐tissue reaction in man after aspirin
24. Effects of salicylates on human platelets
25. Two factors reducing the effectiveness of platelet inhibitors for preventing thrombus formation in stenosed canine coronary arteries
26. Role of platelet‐prostaglandin synthesis in shear induced platelet alterations
27. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries
28. Influence of epinephrine on the aggregation of aspirin treated platelets
29. Morning increase in platelet aggregability
30. Synergism between aspirin and the calcium channel blocker verapamil in inhibiting epinephrine exacerbated platelet thrombus formation in stenosed canine coronary arteries
31. Relative effects of cigarette smoke and ethanol on acute platelet thrombus formation in stenosed canine coronary arteries
32. Alcohol and mortality. The myth of the U‐shaped curve
33. Alcohol and mortality in British men: Explaining the U‐shaped curve
34. Calcium channel blockers and atherogenesis
35. Platelets and atherosclerosis
36. The pathogenesis of atherosclerosis
37. Antithrombotic effect of a monoclonal antibody to a platelet glycoprotein IIb/IIIa receptor in an experimental animal model
38. Acetylsalicylic acid, possible prevention of coronary thrombosis
39. Incidence of myocardial infarction in patients with rheumatoid arthritis
40. Secondary prevention of vascular disease by prolonged antiplatelet treatment
41. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
42. A platelet‐inhibitor drug trial in coronary‐artery bypass operations
43. Improved graft patency in patients treated with platelet‐inhibiting therapy after coronary bypass surgery
44. Correlation of platelet survival time with occlusion of saphenous vein aortocoronary bypass grafts
45. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft potency
46. Randomized placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion
47. Platelet inhibitor drugs before and after coronary bypass surgery and coronary angioplasty: The basis of their use, data from animal studies, clinical trial, and current recommendations
48. Aspirin therapy improves saphenous vein graft patency after coronary artery bypass surgery
49. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative Study
50. The mechanism of the effect of aspiring on human platelets: Acetylation of a particular fraction protein
51. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis
52. Cumulative inhibitory effect of low‐dose aspirin on the vascular prostacyclin and platelet thromboxane production in patients with artherosclerosis
53. Effects of low doses of aspirin and dipyridamole on platelet aggregation in the dog coronary artery
54. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
55. Sex difference in antithrombotic effect of aspirin
56. Preliminary Report: Findings from the aspirin component of the ongoing physicians' health study
57. Randomized trial of prophylactic daily aspirin in British male doctors
58. Dipyridamole
59. The influence on platelet aggregation of drugs that effect the accumulation of adenosine 3′‐5′ cyclic monophosphate in platelets
60. The effect of dipyridamole on platelet function: Correlation with blood levels in man
61. Platelet and fibrinogen consumption in man
62. Drug effect on platelet survival times: Comparison of two pyrimido‐pyrimidine derivatives in patients with aortic or mitral replacements
63. Drug‐induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective double‐blind arteriographically controlled trial
64. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves
65. Pharmacologic control of thrombo‐embolic complications of cardiac‐valve replacement
66. Interaction of platelets with subendothelium in humans treated with aspirin and dipyridamole alone and in combination
67. Effects of dipyridamole and low‐dose aspirin therapy on platelet adhesion to vascular subendothelium
68. The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels
69. Does dipyridamole have antithrombotic potential?
70. Antiplatelet effects of aspirin and dipyridamole
71. Dipyridamole alone or with low dose aspirin does not inhibit thrombus formation in stcnosed canine coronary arteries nor does it protect against renewal of thrombus formation by epinephrine
72. The effects of Persantine (RA8), a new coronary vasodilator, on coronary blood How and cardiac dynamics in the dog
73. Inequalities of myocardial perfusion in coronary artery disease (“coronary steal”)
74. Coronary vasodilator therapy for angina pectoris
75. Effect of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia
76. Effects of dipyridamole‐induced vasodilation on myocardial and clearance kinetics of thallium‐201
77. Thallium‐201 myocardial imaging during coronary vasodilation induced by oral dipyridamole
78. Influence of dipyridamole on myocardial adenosine metabolism
79. Effect of persantine on nucleoside metabolism of the perfused rabbit heart
80. Deleterious effects of dipyridamole during repcrfusion of ischemic myocardium